Role of pharmacokinetics in the discovery and development of indinavir

Advanced Drug Delivery Reviews

Volumn 39, Issue 1-3, 1999, Pages 33-49

  Lin, Jiunn H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Drug drug interactions; Intestinal first pass metabolism; P glycoprotein; pH dependent absorption; Prediction of hepatic clearance; Rational drug design

Indexed keywords

ABSORPTION; DRUG INTERACTIONS; METABOLISM; PH EFFECTS; PHARMACOKINETICS; PROTEINS;

BIOAVAILABILITY; GLYCOPROTEINS;

CONTROLLED DRUG DELIVERY;

CITRIC ACID; CYTOCHROME P450 ISOENZYME; GLYCOPROTEIN P; INDINAVIR; L 364505; L 687908; L 689502; L 732747; L 735482; L 738891; METHYLCELLULOSE; SAQUINAVIR; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL MODEL; BRAIN; DOG; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; HUMAN TISSUE; LIVER; MONKEY; NONHUMAN; PH; PRIORITY JOURNAL; RAT; REVIEW; SPECIES DIFFERENCE;

EID: 0032861326     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00018-6     Document Type: Article

References (54)

1. Lin J.H., Lu A.Y.H. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 49:1997;403-449.
2. Huff J.R. HIV protease: A novel chemotherapeutic target for AIDS. J. Med. Chem. 34:1993;2305-2314.
3. Darke P.L., Huff J.R. HIV protease as an inhibitor target for the treatment of AIDS. Adv. Pharmacol. 25:1994;399-454.
4. Vacca J.P., Dorsey B.D., Schleif W.A., Levin R.B., McDaniel S.L., Darke P.L., Zugay J., Quintero J.C., Blahy O.M., Roth E., Sardana V.V., Schlabach A.J., Graham P.L., Condra J.H., Gotlib L., Holloway M.K., Lin J.H., Chen I.-W., Vastag K., Ostovic D., Anderson P.S., Emini E.A., Huff J.R. L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA. 91:1994;4096-4100.
5. Tomasselli A.G., Howe W.J., Sawyer T.K., Wlidawer A., Heinrikson R.L. The complexities of AIDS: An assessment of the HIV protease as a therapeutic target. Chim. Oggi. 9:1991;6-27.
6. Roberts N.A., Martin J.A., Kinchington D., Broadhurst A.V., Craig J.C., Duncan I.B., Galpin S.A., Handa B.K., Kay J., Kröhn A., Lambert R.W., Merrett J.H., Mills J.S., Parkes K.E.B., Redshaw S., Ritchie A.J., Taylor D.L., Thomas G.J., Machin P.J. Rational design of peptide-based HIV protease inhibitors. Science. 248:1990;358-361.
7. Redshow S. Inhibitors of HIV protease. Exp. Opin. Invest. Drugs. 3:1994;273-286.
8. Wlidawer A., Erickson J.W. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62:1993;543-585.
9. Swain A.L., Miller M.M., Green J., Rich D.H., Schneider J., Kent S.B.H., Wlidawer A. X-ray crystallographic structure of a complex between a synthetic substrate-based hydroxyethylamine inhibitor. Proc. Natl. Acad. Sci. USA. 87:1990;8805-8809.
10. ®, an HIV protease inhibitor. Borchardt R.T., Freidinger R.M., Sawyer T., Smith P. Integration of Pharmaceutical Discovery and Development: Case Histories. 1998;Plenum Press, New York.
11. Vacca J.P., Guare J.P., deSolms S.J., Sanders W.M., Guiliani E.A., Young S.D., Darke P.L., Zugay J., Sigal I.S., Schleif W.A., Quintero J.C., Emini E.A., Anderson P.S., Huff J.R. L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. J. Med. Chem. 34:1991;1225.
12. Thompson W.J., Fitzgerald P.M.D., Holloway M.K., Emini E.A., Darke P.L., McKeever B.M., Schleif W.A., Quintero J.C., Zugay J.A., Tucker T.J., Schwering J.E., Homnick C., Nunberg J., Springer J.P., Huff J.R. Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1′ phenyl substituents: X-ray crystal structure assisted design. J. Med. Chem. 35:1992;1685-1701.
13. Dorsey B.D., Levin R.B., McDaniel S.L., Vacca J.P., Guare J.P., Darke P.L., Zugay J.A., Emini E.A., Schleif W.A., Quintero J.C., Lin J.H., Chen I.-W., Holloway M.K., Fitzgerald P.M.D., Axel M.G., Ostovic D., Anderson P.S., Huff J.R. L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37:1994;3443-3451.
14. Lin J.H. Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. 23:1995;1008-1021.
15. Prentis R.A., Lis Y., Walker S.R. Pharmaceutical innovation by seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol. 25:1988;387-396.
16. Lin J.H., Chen I.-W., Vastag K.J., Ostovic D. pH-Dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab. Dispos. 23:1995;730-735.
17. Debas H.T. Peripheral regulation of gastric acid secretion. Johnson L.R. Physiology of the Gastrointestinal Tract. 1987;931-945 Raven Press, New York. Ch. 31.
18. Ehrlein H.J., Prove J. Effect of viscosity of test meals on gastric emptying in dogs. J. Exp. Physiol. 67:1982;419-425.
19. Petersen H., Grossman M.I. Stimulation of gastric acid secretion by dimaprit in unanesthetized rats. Agents Actions. 8:1978;566-567.
20. 2-receptor antagonists: Relationship between intrinsic potency and effective plasma concentrations. Clin. Pharmacokinet. 20:1991;218-236.
21. Lin J.H., Chiba M., Balani S.K., Chen I.-W., Kwei G.Y.-S., Vastag K.J., Nishime J.A. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency protease inhibitor. Drug Metab. Dispos. 24:1996;1111-1120.
22. Lin J.H., Sugiyama Y., Awazu S., Hanano M. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J. Pharmacokinet. Biopharm. 10:1982;649-661.
23. Dedrick R.L., Zaharko D.S., Lutz R.L. Transport and binding of methotrexate. J. Pharm. Sci. 62:1973;882-890.
24. Chiba M., Hensleigh M., Lin J.H. Hepatic and intestinal metabolism of indinavir, a potent HIV protease inhibitor, in rat and human microsomes. Biochem. Pharmacol. 53:1997;1183-1195.
25. Houston B.J. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47:1994;1469-1479.
26. Houston B.J., Carlile D.J. Prediction of hepatic clearance from microsomes, hepatocytes and liver slices. Drug Metab. Rev. 29:1997;891-922.
27. Iwatsubo T., Hirota N., Ooie T., Suzuki K., Shimada N., Chiba K., Ishizaki T., Green C.E., Tyson C.A., Sugiyama Y. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73:1997;147-171.
28. Wilkinson G.R. Clearance approaches in pharmacology. Pharmacol. Rev. 39:1987;1-47.
29. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:1994;414-422.
30. Wrighton S.A., Vandenbraden M., Stevens J.C., Shipley L.A., Ring B.J., Rettie A.E., Cashman J.R. In vitro methods for assessing human hepatic drug metabolism: Their use in drug development. Drug Metab. Rev. 25:1993;453-484.
31. Balani S.K., Arison B.H., Mathai L., Kauffman L.R., Miller R.R., Stearns R.A., Chen I.-W., Lin J.H. Metabolites of L-735,524, a potent HIV protease inhibitor, in human urine. Drug Metab. Dispos. 23:1995;266-270.
32. Dogterom P. Development of a simple incubation system for metabolism studies with precision-cut liver slices. Drug Metab. Dispos. 21:1993;699-704.
33. Balani S.K., Woolf E.J., Hoagland V.L., Sturgill M.G., Deutsch P.J., Yeh K.C., Lin J.H. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab. Dispos. 24:1996;1389-1394.
34. Chiba M., Hensleigh M., Nishime J.A., Balani S.K., Lin J.H. Role of cytochrome P-450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24:1996;307-314.
35. Rowland M., Matin S.B. Kinetics of drug-drug interactions. J. Pharmacokinet. Biopharm. 1:1973;553-567.
36. VonMoltke L.L., Greenblatt D.J., Grassi J.M., Granda B.W., Duan S.H., Fogelman S.M., Daily J.P., Xarmatz J.S., Shader R.I. Protease inhibitors as inhibitors of human cytochromes P-450: High risk associated with ritonavir. J. Clin. Pharmacol. 36:1998;106-111.
37. Inaba T., Fischer N.E., Riddick D.S., Stewart D.J., Hidaka T. HIV protease inhibitors, saquinavir, indinavir and ritonavir: Inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicol. Lett. 93:1997;215-219.
38. Kempf D.J., Marsh K.C., Kumar G., Rodrigues A.D., Denissen J.F., McDonald E., Kukulka M.J., Hsu A., Granneman G.R., Baroldi P.A., Sun E., Pizzati D., Plattner J.J., Norbeck D.W., Leonard J.M. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:1997;654-660.
39. Higgins C.F. ABC transporters: From microorganism to man. Ann. Rev. Cell Biol. 8:1992;67-113.
40. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug resistance gene product in normal human tissues. Proc. Natl. Acad. Sci. USA. 84:1987;7735-7738.
41. Oldendorf W.H. Brain uptake of radiolabeled amino acids, amines and hexoses after arterial injection. Am. J. Physiol. 221:1971;1629-1639.
42. Pardndge W.M., Mietus L.J. Transport of steroid hormones through the rat blood-brain barrier. J. Clin. Invest. 64:1979;145-154.
43. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J.J., Roden D.M., Wilkinson G.R. The drug transporter p-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:1998;289-294.
44. Lee C.G.L., Gottesman M.M. HIV-1 protease inhibitors and the MDR1 multidrug transporter. J. Clin. Invest. 101:1998;287-288.
45. Wu C.Y., Benet L.Z., Hebert M.F., Gupta S.K., Rowland M., Gomez D.Y., Wacher V.J. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin. Pharmacol. Ther. 58:1995;492-497.
46. Paine M.F., Shen D.D., Kunze K.L., Persins J.D., Marsh C.L., McVicar J.P., Barr D.M., Gillies B.S., Thummel K.E. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 60:1996;14-24.
47. Holtbecker N., Fromm M.F., Kroemer H.K., Ohnhms E.F., Heidemann H. The nifedipine-rifampin interaction: Evidence for induction of gut wall metabolism. Drug Metab. Dispos. 24:1996;1121-1123.
48. Fromm M.F., Busse D., Kroemer H.K., Eichelbauru M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology. 24:1996;796-801.
49. Watkins P.B., Wrighton S.A., Schuetz E.G., Molowa D.T., Guzelian P.S. Identification of glucocorticoid cytochrome P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80:1987;1029-1036.
50. deWaziers I., Cugenec P.H., Yang C.S., Lerous J.P., Beaune P.H. Cytochrome P-450 isoenzymes, epoxide hydrolase and glutathione transferase in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253:1990;387-394.
51. Thummel K.E., Kunze K.L., Shen D.D. Enzyme-catalyzed process of first-pass hepatic and intestinal drug extraction. Adv. Drug Deliv. Rev. 27:1997;99-127.
52. Houston J.B. Utility of in vitro drug metabolism data in prediction of in vivo metabolic clearance. Biochem. Pharmacol. 47:1994;1469-1479.
53. Borm P., Frankhuijzen-Sierevogel A., Noordhoek J. Time and dose dependence of 3-methylcholanthrene-induced metabolism in rat intestinal mucosal cells and microsomes. Biochem. Pharmacol. 31:1982;3707-3710.
54. Gan S., Moseley M.A., Khosla B., Augustijins P.F., Bradshaw T.P., Hendren R.W., Thakker D.R. CYP3A-like cytochrome P-450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab. Dispos. 24:1996;344-349.